PRESS RELEASE published on 10/17/2025 at 13:05, 5 months ago Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia CHMP recommends Sanofi's Wayrilz for EU approval to treat immune thrombocytopenia, targeting disease root cause through multi-immune modulation. Positive phase 3 study results showcased rapid platelet response and symptom improvements Sanofi CHMP Wayrilz Immune Thrombocytopenia Multi-immune Modulation
PRESS RELEASE published on 10/17/2025 at 13:00, 5 months ago Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies EU Sanofi CHMP Rezurock CGVHD
BRIEF published on 10/08/2025 at 07:05, 5 months 9 days ago AlphaMedixTM: Positive Phase 2 Results for the Treatment of GEP-NETs Clinical Trial Phase 2 Innovative Therapy AlphaMedixTM TNE-GEP
BRIEF published on 09/24/2025 at 07:10, 5 months 23 days ago Sanofi invests $625 million to boost Sanofi Ventures Innovation Digital Health Investment Sanofi Biotechnologies
BRIEF published on 09/24/2025 at 07:05, 5 months 23 days ago Sanofi Releases Q3 2025 Aide Mémoire Investor Relations Sanofi Financial Modeling Results Announcement Q3 2025
PRESS RELEASE published on 09/24/2025 at 07:05, 5 months 23 days ago Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation Sanofi commits $625 million to Sanofi Ventures to boost biotech and digital health investments. Focus on immunology, rare diseases, neurology, vaccines Digital Health Investment Biotech Ventures Sanofi
PRESS RELEASE published on 09/24/2025 at 07:00, 5 months 23 days ago Press release: Availability of the Q3 2025 Aide mémoire Sanofi announces availability of Q3 2025 Aide mémoire for financial modeling purposes. Document covers non-comparable items, foreign currency impact, and share count Investors Sanofi Financial Modeling Aide Mémoire Q3 2025
BRIEF published on 09/23/2025 at 07:05, 5 months 24 days ago Sanofi's SAR446268 Therapy Advances in the United States Gene Therapy Sanofi SAR446268 FDA Admission Myotonic Dystrophy
PRESS RELEASE published on 09/23/2025 at 07:00, 5 months 24 days ago Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need AAV Gene Therapy Sanofi Fast Track Designation SAR446268 Myotonic Dystrophy Type 1
BRIEF published on 09/17/2025 at 07:05, 6 months ago Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment Brivekimig Hidradenitis Suppurativa Phase 2a Study Nanobody Technology Immune-mediated Diseases
Published on 03/18/2026 at 01:25, 3 hours 48 minutes ago Zeus North America Mining Corp. Announces Upsizing and Closing of Final Tranche of Private Placement
Published on 03/18/2026 at 00:30, 4 hours 43 minutes ago Panther Minerals Announces Appointment of Rick Mah as Chief Financial Officer
Published on 03/18/2026 at 00:30, 4 hours 43 minutes ago Core Critical Metals Corp. Announces Non-Brokered LIFE Offering and Concurrent Private Placement
Published on 03/17/2026 at 23:59, 5 hours 14 minutes ago Presentation to Swiss Mining Institute Conference
Published on 03/17/2026 at 23:10, 6 hours 3 minutes ago Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 23:43, 5 hours 30 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C - Daily buy back notice
Published on 03/17/2026 at 21:21, 7 hours 52 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 8 hours 17 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 11 hours 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 22 hours 13 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 11 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 11 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 11 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026